spacer
home > white papers > eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials - Clinical Ink
WHITE PAPERS

Clinical Ink

phone 1-800-301-5033
email info@clinicalink.com
web http://www.clinicalink.com
email 525 Vine Street, Suite 130, Winston-Salem, NC 27101

eSource: Reducing Site Workload for Better, Faster, Safer Clinical Trials

More sponsors and CROs are looking for new ways to better leverage investigative site relationships to improve clinical trial performance. To this end, some clinical organizations have adopted electronic source (eSource) to help improve study quality and efficiency - for both sponsor and site. Unlike traditional electronic data capture (EDC), SureSource, Clinical Ink’s eSource platform, was designed from the beginning to minimize clinical trial complexity for site users. As SureSource adoption increased, study teams began to see an improvement in data quality, operational efficiency and ease of use compared to traditional methods (paper and EDC). A Site Impact Survey provides scientific evidence regarding the impact of SureSource from 517 site users. Results confirm it significantly reduces workload, lessens queries, and improves data quality compared to paper and EDC. In this white paper, we quantitatively evaluate survey outcomes, provide qualitative feedback from survey respondents, and highlight the observed benefits of SureSource for transforming clinical research.
spacer

Member login

E-mail address:

Password:
Remember me


News and Press Releases

Porton Biopharma opens new facility to make more of its childhood cancer cure

In a ribbon cutting ceremony, John Glen MP for Salisbury and South Wiltshire today (27th April 2018) officially opened Porton Biopharma Limited’s (PBL) new fermentation facility which will be used to manufacture the company’s life-saving leukaemia drug Erwinase®.   
More info >>


White Papers

Biosimilars In Emerging Markets: Is It A Level Playing Field?

PRA Health Sciences (PRA)

Governments, healthcare payers, and social and health reforms, combined with the increased incidence of conditions such as cancer and diabetes are paving the way for increased uptake of biologic medicines in emerging markets. However, expensive biologic medicines can be prohibitive to many patients, creating a high level of unmet clinical need. At its best, the global expansion of biosimilars can mean a robust and steady supply of existing and new drugs reaching far-flung patient populations, but localized biosimilar drug developments, especially in China and India, combined with a lack of robust pharmacovigilance systems, threaten to derail the industry by putting patient health at risk.
More info >>


Industry Events

Symposium on Digitalization and Big Data in Biotech and Pharma

6 June 2018, ETH Zurich, Institute for Chemical and Bioengineering, Vladimir-Prelog-Weg 1

The Symposium on Digitalization and Big Data in Biotech & Pharma will bring together experts and key stakeholders from industry and academia to discuss and current digital innovations and technological trends in the pharmaceutical sector.
More info >>


©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement